{
  "source": "PA-Notification-Pyrukynd.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1387-4\nProgram Prior Authorization/Notification\nMedication Pyrukynd® (mitapivat)\nP&T Approval Date 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nPyrukynd® (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic\nanemia in adults with pyruvate kinase (PK) deficiency.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Pyrukynd will be approved based on both of the following criteria:\na. Diagnosis of pyruvate kinase (PK) deficiency\n-AND-\nb. Used for the treatment of hemolytic anemia\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Pyrukynd will be approved based on one of the following criteria:\na. Documentation of positive clinical response to Pyrukynd therapy\nAuthorization will be issued for 12 months.\n-OR-\nb. Documentation does not provide evidence of positive clinical response to Pyrukynd\ntherapy, allow for dose titration with discontinuation of therapy\nAuthorization will be issued for 4 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Pyrukynd [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc.; February\n2022.\nProgram Prior Authorization/Notification - Pyrukynd® (mitapivat)\nChange Control\n5/2022 New program\n5/2023 Annual review. Added state mandate footnote.\n5/2024 Annual review. Updated initial criteria approval to 12 months.\n5/2025 Annual review. No changes to coverage criteria.\n© 2",
    "\n5/2022 New program\n5/2023 Annual review. Added state mandate footnote.\n5/2024 Annual review. Updated initial criteria approval to 12 months.\n5/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}